Kinnate Biopharma Price Prediction

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
At the present time, the value of RSI of Kinnate Biopharma's share price is approaching 47. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Kinnate Biopharma, making its price go up or down.

Oversold Vs Overbought

47

 
Oversold
 
Overbought
The successful prediction of Kinnate Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Kinnate Biopharma and does not consider all of the tangible or intangible factors available from Kinnate Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with Kinnate Biopharma, which may create opportunities for some arbitrage if properly timed.
Using Kinnate Biopharma hype-based prediction, you can estimate the value of Kinnate Biopharma from the perspective of Kinnate Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Kinnate Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Kinnate because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Kinnate Biopharma after-hype prediction price

    
  USD 2.96  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kinnate Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
2.712.713.26
Details
Naive
Forecast
LowNextHigh
2.762.762.76
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.863.103.34
Details

Kinnate Biopharma After-Hype Price Prediction Density Analysis

As far as predicting the price of Kinnate Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kinnate Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kinnate Biopharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Kinnate Biopharma Estimiated After-Hype Price Volatility

In the context of predicting Kinnate Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kinnate Biopharma's historical news coverage. Kinnate Biopharma's after-hype downside and upside margins for the prediction period are 2.96 and 2.96, respectively. We have considered Kinnate Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
2.96
2.96
After-hype Price
2.96
Upside
Kinnate Biopharma is very steady at this time. Analysis and calculation of next after-hype price of Kinnate Biopharma is based on 3 months time horizon.

Kinnate Biopharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Kinnate Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kinnate Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kinnate Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
1 Events / Month
16 Events / Month
Very soon
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
2.96
2.96
0.00 
0.00  
Notes

Kinnate Biopharma Hype Timeline

Kinnate Biopharma is now traded for 2.96. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Kinnate is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Kinnate Biopharma is about 0.0%, with the expected price after the next announcement by competition of 2.96. About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.79. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kinnate Biopharma recorded a loss per share of 2.78. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be very soon.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Kinnate Biopharma Related Hype Analysis

Having access to credible news sources related to Kinnate Biopharma's direct competition is more important than ever and may enhance your ability to predict Kinnate Biopharma's future price movements. Getting to know how Kinnate Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kinnate Biopharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
AMAMAmbrx Biopharma American 0.00 0 per month 4.78  0.09  6.05 (7.28) 29.96 
SLRNACELYRIN, INC Common 0.23 6 per month 0.00 (0.03) 8.55 (8.30) 28.93 
WINTWindtree Therapeutics(0.04)7 per month 0.00 (0.27) 12.00 (18.48) 60.67 
PALIPalisade Bio 0.03 7 per month 0.00 (0.11) 5.97 (8.55) 24.25 
IPSCCentury Therapeutics(0.05)8 per month 0.00 (0.03) 7.44 (8.82) 21.67 
PASGPassage Bio 0.03 8 per month 5.96 (0.01) 10.00 (10.45) 25.50 
FIXXHomology Medicines(0.01)2 per month 3.52  0.01  5.77 (5.61) 19.43 
GBIOGeneration Bio Co(0.01)5 per month 0.00 (0.18) 9.35 (8.20) 25.48 
STOKStoke Therapeutics(0.04)10 per month 0.00 (0.08) 4.68 (6.99) 21.35 
GRCLGracell Biotechnologies 0.07 53 per month 6.35  0.16  16.34 (6.25) 52.11 
THRXTheseus Pharmaceuticals 0.14 2 per month 0.00 (0.06) 11.75 (8.57) 90.33 
GLUEMonte Rosa Therapeutics(0.74)8 per month 3.86  0.07  7.42 (8.18) 102.66 
DSGNDesign Therapeutics(0.24)5 per month 5.14  0.06  9.43 (7.45) 35.31 
ERASErasca Inc(0.02)6 per month 3.55  0.01  7.34 (5.19) 17.38 
KRONKronos Bio 0.01 8 per month 3.32 (0.04) 5.75 (6.25) 16.20 
CCCCC4 Therapeutics(0.35)10 per month 0.00 (0.11) 8.59 (7.98) 23.66 
EWTXEdgewise Therapeutics 1.60 10 per month 2.79  0.11  6.65 (4.70) 61.02 
SRZNSurrozen(0.75)5 per month 4.87  0.03  16.74 (7.91) 33.59 
BOLTBolt Biotherapeutics 0.00 10 per month 0.00 (0.09) 4.84 (4.48) 14.96 
LRMRLarimar Therapeutics(0.49)9 per month 0.00 (0.05) 10.87 (9.55) 26.71 
KROSKeros Therapeutics(0.79)9 per month 2.19  0.11  4.39 (4.31) 16.94 
KZRKezar Life Sciences(0.20)7 per month 2.77  0.04  4.93 (3.88) 51.13 

Kinnate Biopharma Additional Predictive Modules

Most predictive techniques to examine Kinnate price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kinnate using various technical indicators. When you analyze Kinnate charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Kinnate Biopharma Predictive Indicators

The successful prediction of Kinnate Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kinnate Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kinnate Biopharma based on analysis of Kinnate Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kinnate Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kinnate Biopharma's related companies.

Story Coverage note for Kinnate Biopharma

The number of cover stories for Kinnate Biopharma depends on current market conditions and Kinnate Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kinnate Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kinnate Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Kinnate Biopharma Short Properties

Kinnate Biopharma's future price predictability will typically decrease when Kinnate Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kinnate Biopharma often depends not only on the future outlook of the potential Kinnate Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kinnate Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding46.6 M
Cash And Short Term Investments154 M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Transaction History
View history of all your transactions and understand their impact on performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges